论文部分内容阅读
目的观察氯雷他定(开瑞坦)糖浆口服治疗小儿支原体肺炎的临床疗效。方法 2013年1月至12月诊断为肺炎支原体肺炎,症状体征相似,且年龄4~12岁的92例住院患儿,按随机数字表法分为对照组42例与观察组50例,在抗感染的基础上观察组给予开瑞坦糖浆口服,观察比较两组疗效。结果观察组患儿体温恢复正常时间为(2.34±1.00)d,与对照组的(2.88±1.58)d比较,差异无统计学意义(P>0.05);观察组患儿咳嗽消失时间(5.78±1.60)d、肺部罗音消失时间(5.18±1.89)d及住院时间(7.54±2.15)d,均较对照组[(7.48±1.94)d、(7.40±1.80)d、(9.33±2.18)d]缩短(P均<0.01);观察组与对照组患儿总有效率、痊愈率比较差异无统计学意义(P均>0.05)。结论开瑞坦糖浆可以辅助治疗小儿支原体肺炎,有利于加快临床症状的消失,缩短住院时间。
Objective To observe the clinical efficacy of loratadine (Kaitai Tan) syrup oral treatment of children with mycoplasma pneumonia. Methods From January to December 2013, 92 hospitalized children with Mycoplasma pneumoniae pneumonia who had similar signs and symptoms and aged 4 to 12 years were divided into control group (n = 42) and observation group (n = 50) according to random number table. On the basis of infection, the observation group was given Kelitan syrup orally, and the curative effect was observed and compared between the two groups. Results The body temperature returned to normal in observation group was (2.34 ± 1.00) d, and there was no significant difference between the observation group and the control group (2.88 ± 1.58) d (P> 0.05). The disappearance time of cough in observation group (7.40 ± 1.80) d, (9.33 ± 2.18) d, 1.60 d, 5.18 ± 1.89 d, and 7.54 ± 2.15 d respectively in the control group [(7.48 ± 1.94) d, d] (all P <0.01). There was no significant difference between the observation group and the control group in the total effective rate and the cure rate (all P> 0.05). Conclusion Kai Ruitan syrup can help treat children with mycoplasma pneumonia, help to speed up the disappearance of clinical symptoms, shorten the hospital stay.